Whilst in New Delhi, Julie and Leonita will also attend the World IP Forum during 14-16 November. This year’s theme for the Forum is Global Innovation 2020: A Strategic Vision for Economic Growth. Both Julie and Leonita have, between them, decades of experience as Chartered and European Patent Attorneys practising in the life sciences and related industries. Leonita also practised as an Indian Patent & Designs Attorney before joining AA Thornton. Julie spent many years in-house, particularly in multinational pharmaceutical companies. Participants in the Forum are from across the globe, including UK, US, mainland Europe, Asia and Australasia, and include representatives of Apple, Bayer, Dow Chemical, Ericsson, GE, Google, Honeywell, IBM, Mastercard, Mylan, Nokia, NovoNordisk, Pfizer, Philips, Roche, Samsung, Tata, Unichem and Unilever, and the European Patent Office (EPO) and US patent & trademark office (USPTO).
As a member of CIPA’s International Liaison Committee, Julie is honoured to also be attending a joint meeting with representatives of the Asian Patent Attorney Association (APAA) in New Delhi on 15 November. The meeting will involve an exchange of news, views and legal updates, including on topics such as antibody patenting, designs, trade marks, patenting in the area of artificial intelligence and the impact of Brexit on intellectual property. Julie will be speaking on the subject of Extensions and Exemptions to Pharmaceutical Patent Protection in Europe. The meeting will be followed at a reception at the British High Commission.
Both will then attend the APAA conference that is set to place during 17 – 21 November.
On Thursday 22nd November, Julie will be delivering a training workshop on European patent drafting and prosecution to the Council of Scientific & Industrial Research (CSIR). In this workshop, given in association with Indian IP firm LexOrbis, Julie will be focusing on the downstream and commercial considerations to be taken into account, even at the initial filing/priority document stage, in the life sciences field. A separate session will also look at the Unified Patent Court Agreement, and will anticipate the arrival in due course of the European Patent having unified affect, together with any impact of Brexit on patent protection in Europe.